Year-end report January-December 2009
(Thomson Reuters ONE) -
* The Group's sales for the period amounted to SEK 634 (580) million
* EBITDA amounted to SEK 98 (72) million
* EBIT amounted to SEK 71(1)()) (57) million
* The net profit after tax for the period amounted to SEK 18(1)) (32)
million(2))
* Earnings per share after tax for the period were SEK 0.05 (0.13 )(2) )before
and after dilution
Significant events during the period
* The capital acquisition implemented in Q2 was fully subscribed, bringing
BioPhausia proceeds of SEK 64 million before expenses.
* Generic product sales were launched in Poland towards the end of Q3.
* Novalucol was named as one of the limited number of non-prescription drugs
cleared for sale in the large supermarket chains.
* In the 3rd quarter, 58% of the available warrants under the incentive
programme were acquired by personnel.
Period October-December
* The Group's sales for the quarter amounted to SEK 153 (168) million
* EBITDA amounted to SEK 23 (23) million
* Operating profit was SEK 13(1) )(18) million
* Profit after tax amounted to SEK 2(1)) (-2) million
* Earnings per share after tax was SEK 0.01 (neg) before and after dilution
Significant events after the period
* Claes Thulin is to leave BioPhausia. Recruitment of a new CEO is underway.
* The Board has decided to initiate a process to review the communicated
financial targets.
Stockholm 12 of February 2010
CLAES THULIN
CHIEF EXECUTIVE OFFICER
FOR FURTHER INFORMATION
Claes Thulin CEO, +46-8-407 64 30
www.biophausia.se
[HUG#1385233]
Year-end report January-December 2009: http://hugin.info/130049/R/1385233/344002.pdf
Unternehmensinformation / Kurzprofil:
Datum: 17.02.2010 - 08:47 Uhr
Sprache: Deutsch
News-ID 12596
Anzahl Zeichen: 0
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 204 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Year-end report January-December 2009"
steht unter der journalistisch-redaktionellen Verantwortung von
BioPhausia AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
